Companies cannot patent specific pieces of DNA, the US Supreme Court declared yesterday in a mixed decision that also affirmed the rights of the $83bn biotechnology industry in synthetic genetic products.
美国最高法院(US Supreme Court)昨日宣告，企业不能为具体的DNA片段申请专利，但这一胜负参半的判决也确认了规模达830亿美元的生物技术行业对于合成基因产品的权利。
您已阅读14%（293字），剩余86%（1828字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。